FDA's Biosimilar Rule Cutting Biocon's Drug Costs

Biocon, a leading Indian pharmaceutical company, anticipates a significant reduction in biosimilar drug development costs following the U.S. FDAs proposal to simplify clinical testing. This could potentially halve development expenses, accelerate time-to-market, and make these life-saving treatments more affordable. Biocon plans to launch twenty biosimilars by 2030, with a focus on the U.S. and European markets. Currently, seven biosimilars are commercially available in the U.S., and the company is poised to introduce two more within the next six months.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.